Immunocore

Immunocore: Developer of the world’s first approved TCR-therapeutic KIMMTRAK and pioneering a new class of therapeutics to deliver transformative medicines to patients in cancer, infection, and autoimmune. KIMMTRAK generated net revenues of $34M in 2Q22 for patients with metastatic uveal melanoma. Durable clinical activity was presented (ESMO 2022) for PRAME in multiple solid tumors and have initiated four expansion arms.

Sector/Industry:

Healthcare/Biotechnology

Characteristics:

Based in...

Europe

Clinical Stage

Marketed, Phase III, Phase l or ll

Disease Space

Anti-infectives, Antivirals, Immuno-Oncology, Immunotherapy, Infectious Disease, Oncology, Rare Disease

Finance

Revenues

Industry

Biotechnology

Listing

Public, USA

Market Cap

1B +

Therapeutic Modalities

Antibodies, Cell Therapy, Platform Technology

Website:

http://www.immunocore.com/

Profiles:

Address:

Abingdon, Oxfordshire
United Kingdom

Presentation:

Please reach out to Solebury Strategic Communications to request a presentation

More info:

Send Message to Request Information

My account:

Company Participants at Solebury 1x1 Management Access Event 2023

Bahija Jallal, CEO
Brian Di Donato, Chief Financial Officer and Head of Strategy
Clayton Robertson, Head of Investor Relations
David Berman, Head of R&D

Lead Programs

Kimmtrak

Indication	Phase
metastatic uveal Melanoma	Marketed
Advanced Melanoma	2/3

Top 10 Holders of Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh

Institution	OS (%)	Position	Mkt Val ($MM)	Source	Filing Date
RTW Investments LP	12.27	5,559,322	283.75	13F	12/31/22
Rock Springs Capital Management LP	7.33	3,321,066	169.51	13F	12/31/22
Baker Bros. Advisors LP	5.56	2,520,731	128.66	13F	12/31/22
Wellington Management Co. LLP	4.75	2,152,966	109.89	13F	12/31/22
Fidelity Management & Research Co. LLC	3.97	1,797,746	91.76	13F	12/31/22
T. Rowe Price Associates, Inc. (Investment Management)	2.94	1,333,916	68.08	13F	12/31/22
Avidity Partners Management LP	2.55	1,154,000	58.90	13F	12/31/22
General Atlantic LLC	2.10	950,000	48.49	13F	12/31/22
Paradigm BioCapital Advisors LP	1.89	857,925	43.79	13F	12/31/22
Pictet Asset Management SA	1.36	618,315	31.56	13F	12/31/22

Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...

Market Data copyright © 2023 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.